Celltrion Pharm achieved its highest-ever quarterly operating profit in the second quarter of this year.
In a preliminary earnings disclosure on the 4th, Celltrion Pharm said it recorded revenue of 153.3 billion won and operating profit of 19.3 billion won in the second quarter. The figures represent increases of 16.8% in revenue and 24.4% in operating profit from a year earlier, marking a record quarterly operating profit. Celltrion Pharm explained that "stable sales performance of chemical drugs, expanded prescriptions of the biosimilar product lineup, and increased production volume of pre-filled syringes (PFS) driven by rising global demand led the profit growth."
In detail, the chemical drug business recorded revenue of 67 billion won. Its flagship product, the liver treatment "Godex," grew 10.1% to 17.7 billion won. Bio business revenue rose 12.5% from a year earlier to 36.6 billion won, with the autoimmune disease treatment "Remsima" up 19.2% to 11.5 billion won and the blood cancer treatment "Truxima" up 20.7% to 4.3 billion won. The allergy treatment "Omlyclo" also recorded revenue of 1.2 billion won, up 206.5%, on the back of expanded new prescriptions at major hospitals.
The contract manufacturing segment grew 53.4% from a year earlier to 49.7 billion won. As PFS product production volume increased amid expanding global market demand, related commercial production revenue rose 51.9% to 35.3 billion won.
A Celltrion Pharm official stressed, "In the second half as well, we will continue to strengthen the sales competitiveness of our flagship products and maintain production capabilities that can flexibly respond to market demand, sustaining a stable growth foundation."
